Objective: In this study, we aimed to present the demographical, histopathological and clinical features of the cases diagnosed as Hodgkin lymphoma; and to determine the effects of negative prognostic grouping in early stage (stage I-II) of Hodgkin lymphoma and International Prognostic Score in late stage (stage III-IV) Hodgkin lymphoma on the survival of the patients. Methods: The data of the 46 patients diagnosed with Hodgkin lymphoma followed in our center for seven years has been evaluated retrospectively. Results: Demographical, histopathological and clinical features of the cases are shown in the table 1. The primary treatments were %80.4 ABVD combination chemotheraphy and %19.6 chemotheraphy+radiotheraphy. Treatment methods and disease response rates are shown in the table 2. It was identified that there was an early relapse in the %69 and a late relapse in the %31 of the patients whose diseases relapsed after the primary treatment. The autologous stem cell transplants were done for the %60 of the patients. The median follow-up time was 22 months (change between 4-70). The rate of 5-year-overall survival (OS) was %87 and the rate of the relapse-free survival (RFS) was %71.7. As there was a significant difference between the genders in terms of OS rates, there was not for RFS rates (resp., p=0.01;p=0.07). When the patients were examined due to their responses to the primary treatment, there was a significant difference OS and RFS rates (p=0.002 ; p<0.001). Furthermore; a significant difference among overall survival rates was identified according to the relapse progression(p=0.019). When a classification of positive and negative prognostic groups was done in terms of German Hodgkin Study Group (GHSG), European Organisation for Research and Treatment of Cancer (EORTC), The National Comprehensive Cancer Network (NCCN) and National Centre for Infections in Cancer (NCIC), no significant difference was found between the rates of OS and RFS (p>0.05). Moreover, in our study, no significant difference among International Prognostic Score, OS and RFS rates was found. Conclusion: The treatment chart must be designed as taking the stage of the disease and the prognostic factors into consideration. So, the progression risk of the toxidity and treatment complication in long term can be minimized.
Corresponding Author: Ozturan A.